| 1 |
35371054 | Indoleamine 2, 3-Dioxygenase 1 Mediates Survival Signals in Chronic Lymphocytic Leukemia via Kynurenine/Aryl Hydrocarbon Receptor-Mediated MCL1 Modulation. | 2022 |
2 |
| 2 |
35507130 | Ex vivo effect of JAK inhibition on JAK-STAT1 pathway hyperactivation in patients with dominant-negative STAT3 mutations. | 2022 May 4 |
4 |
| 3 |
33475942 | Stepwise Reversal of Immune Dysregulation Due to STAT1 Gain-of-Function Mutation Following Ruxolitinib Bridge Therapy and Transplantation. | 2021 May |
3 |
| 4 |
33501441 | Interferon-regulated genetic programs and JAK/STAT pathway activate the intronic promoter of the short ACE2 isoform in renal proximal tubules. | 2021 Jan 19 |
1 |
| 5 |
33517393 | Mosaic IL6ST variant inducing constitutive GP130 cytokine receptor signaling as a cause of neonatal onset immunodeficiency with autoinflammation and dysmorphy. | 2021 Apr 26 |
1 |
| 6 |
33747209 | Ruxolitinib induces apoptosis of human colorectal cancer cells by downregulating the JAK1/2-STAT1-Mcl-1 axis. | 2021 May |
3 |
| 7 |
33965175 | Ruxolitinib Inhibits IFNγ Licensing of Human Bone Marrow Derived Mesenchymal Stromal Cells. | 2021 May |
5 |
| 8 |
34109505 | SARS-CoV-2 infection in a pediatrics STAT1 GOF patient under Ruxolitinib therapy-a matter of balance? | 2021 Oct |
1 |
| 9 |
34771447 | Intrinsic Interferon Signaling Regulates the Cell Death and Mesenchymal Phenotype of Glioblastoma Stem Cells. | 2021 Oct 21 |
1 |
| 10 |
34943910 | A Functional Precision Medicine Pipeline Combines Comparative Transcriptomics and Tumor Organoid Modeling to Identify Bespoke Treatment Strategies for Glioblastoma. | 2021 Dec 2 |
1 |
| 11 |
32180118 | Ruxolitinib treatment of a patient with steroid-dependent severe autoimmunity due to STAT1 gain-of-function mutation. | 2020 Aug |
2 |
| 12 |
32492985 | The Dose Dependent Effects of Ruxolitinib on the Invasion and Tumorigenesis in Gliomas Cells via Inhibition of Interferon Gamma-Depended JAK/STAT Signaling Pathway. | 2020 Jul |
8 |
| 13 |
32698510 | The Effect of JAK Inhibitor on the Survival, Anagen Re-Entry, and Hair Follicle Immune Privilege Restoration in Human Dermal Papilla Cells. | 2020 Jul 20 |
2 |
| 14 |
32732635 | Ruxolitinib Response in an Infant With Very-early-onset Inflammatory Bowel Disease and Gain-of-function STAT1 Mutation. | 2020 Oct |
1 |
| 15 |
32758351 | Signal transducer and activator of transcription (STAT) 1 and STAT3 are expressed in the human ovary and have Janus kinase 1-independent functions in the COV434 human granulosa cell line. | 2020 Aug |
1 |
| 16 |
30030153 | HMGB1/RAGE Mediates UVB-Induced Secretory Inflammatory Response and Resistance to Apoptosis in Human Melanocytes. | 2019 Jan |
1 |
| 17 |
30622322 | JAK/STAT inhibition with ruxolitinib enhances oncolytic virotherapy in non-small cell lung cancer models. | 2019 Nov |
1 |
| 18 |
30655323 | Interaction Between MUC1 and STAT1 Drives IFITM1 Overexpression in Aromatase Inhibitor-Resistant Breast Cancer Cells and Mediates Estrogen-Induced Apoptosis. | 2019 May |
1 |
| 19 |
31182137 | AKR1C1 controls cisplatin-resistance in head and neck squamous cell carcinoma through cross-talk with the STAT1/3 signaling pathway. | 2019 Jun 10 |
1 |
| 20 |
31512162 | Novel Gain-of-Function Mutation in Stat1 Sumoylation Site Leads to CMC/CID Phenotype Responsive to Ruxolitinib. | 2019 Nov |
1 |
| 21 |
29111217 | Ruxolitinib partially reverses functional natural killer cell deficiency in patients with signal transducer and activator of transcription 1 (STAT1) gain-of-function mutations. | 2018 Jun |
6 |
| 22 |
29934865 | Utility of Ruxolitinib in a Child with Chronic Mucocutaneous Candidiasis Caused by a Novel STAT1 Gain-of-Function Mutation. | 2018 Jul |
4 |
| 23 |
30035369 | Epidermal growth factor induces STAT1 expression to exacerbate the IFNr-mediated PD-L1 axis in epidermal growth factor receptor-positive cancers. | 2018 Nov |
1 |
| 24 |
30224514 | IL-17A Attenuates IFN-λ Expression by Inducing Suppressor of Cytokine Signaling Expression in Airway Epithelium. | 2018 Oct 15 |
1 |
| 25 |
28139313 | Ruxolitinib reverses dysregulated T helper cell responses and controls autoimmunity caused by a novel signal transducer and activator of transcription 1 (STAT1) gain-of-function mutation. | 2017 May |
3 |
| 26 |
29226168 | Risks of Ruxolitinib in STAT1 Gain-of-Function-Associated Severe Fungal Disease. | 2017 Fall |
2 |
| 27 |
26787170 | Ruxolitinib Induces Interleukin 17 and Ameliorates Chronic Mucocutaneous Candidiasis Caused by STAT1 Gain-of-Function Mutation. | 2016 Apr 1 |
1 |
| 28 |
27379765 | Severe Early-Onset Combined Immunodeficiency due to Heterozygous Gain-of-Function Mutations in STAT1. | 2016 Oct |
1 |
| 29 |
25662309 | Use of ruxolitinib to successfully treat chronic mucocutaneous candidiasis caused by gain-of-function signal transducer and activator of transcription 1 (STAT1) mutation. | 2015 Feb |
2 |